Inhibrx Biosciences, Inc.
INBX
$89.39
$0.290.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 550.00% | 550.00% | -19.26% | -24.45% | -88.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 550.00% | 550.00% | -19.26% | -24.45% | -88.78% |
| Cost of Revenue | -42.66% | -44.52% | -52.05% | -47.78% | -18.95% |
| Gross Profit | 43.33% | 45.11% | 52.28% | 47.95% | 18.38% |
| SG&A Expenses | -81.46% | -81.79% | -71.12% | -68.90% | 276.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -58.65% | -58.89% | -58.16% | -54.56% | 19.80% |
| Operating Income | 59.05% | 59.26% | 58.34% | 54.71% | -20.57% |
| Income Before Tax | -107.56% | -108.30% | -109.45% | -110.02% | 735.43% |
| Income Tax Expenses | 0.00% | 0.00% | 200.00% | -- | -33.33% |
| Earnings from Continuing Operations | -107.56% | -108.30% | -109.45% | -110.02% | 735.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.56% | -108.30% | -109.45% | -110.02% | 735.42% |
| EBIT | 59.05% | 59.26% | 58.34% | 54.71% | -20.57% |
| EBITDA | 59.48% | 59.73% | 58.84% | 55.30% | -20.14% |
| EPS Basic | -107.09% | -107.84% | -108.99% | -109.62% | 653.23% |
| Normalized Basic EPS | 57.87% | 60.48% | 62.46% | 62.56% | 6.91% |
| EPS Diluted | -107.19% | -107.95% | -109.12% | -109.77% | 645.65% |
| Normalized Diluted EPS | 57.57% | 60.23% | 62.26% | 62.37% | 7.58% |
| Average Basic Shares Outstanding | 1.71% | 4.65% | 8.08% | 15.49% | 22.37% |
| Average Diluted Shares Outstanding | 1.39% | 4.32% | 7.73% | 15.08% | 22.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |